losartan has been researched along with Sensitivity and Specificity in 49 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "From our preliminary results, we conclude that losartan is not superior to captopril renography for the detection of haemodynamically significant renal artery stenosis." | 9.11 | Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing. ( Altun, B; Caner, B; Cil, B; Ergün, EL; Günay, EC; Hekimoğlu, B; Oztürk, MH; Salanci, BV; Uğur, O, 2005) |
| "The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women." | 9.09 | Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2001) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| " We prospectively compared MWS derived from linear echocardiographic dimensions with MR strain(in) in septal and posterior locations in 27 subjects with ECG LV hypertrophy in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 7.74 | Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. ( Bella, JN; Biederman, RW; Calhoun, D; Dell'Italia, LJ; Devereux, RB; Doyle, M; Kortright, E; Oparil, S; Perry, G; Pohost, GM; Young, AA, 2008) |
| "The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol." | 7.72 | How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? ( Dawson, A; Donnelly, LA; Morris, AD; Pringle, SD; Rana, BS; Struthers, AD, 2004) |
| "From our preliminary results, we conclude that losartan is not superior to captopril renography for the detection of haemodynamically significant renal artery stenosis." | 5.11 | Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing. ( Altun, B; Caner, B; Cil, B; Ergün, EL; Günay, EC; Hekimoğlu, B; Oztürk, MH; Salanci, BV; Uğur, O, 2005) |
| "The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women." | 5.09 | Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2001) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| " We prospectively compared MWS derived from linear echocardiographic dimensions with MR strain(in) in septal and posterior locations in 27 subjects with ECG LV hypertrophy in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 3.74 | Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. ( Bella, JN; Biederman, RW; Calhoun, D; Dell'Italia, LJ; Devereux, RB; Doyle, M; Kortright, E; Oparil, S; Perry, G; Pohost, GM; Young, AA, 2008) |
| "The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol." | 3.72 | How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? ( Dawson, A; Donnelly, LA; Morris, AD; Pringle, SD; Rana, BS; Struthers, AD, 2004) |
| " Based on the 90% confidence interval of the individual ratios for Cmax and AUC0-inf, it was concluded that the test formulation is bioequivalent to the reference Hyzaar formulation with respect to the rate and extent of absorption of both LOS and HCTZ." | 2.74 | Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. ( Andraus, MH; Azevedo, CP; Borges, BC; Borges, NC; Moreira, RF; Moreno, RA; Salvadori, MC, 2009) |
| "Losartan-treated human dermal fibroblasts displayed decreased contractile activity, migration, and gene expression of transforming growth factor-β1, collagen I, and monocyte chemoattractant protein-1 relative to controls (p < 0." | 1.51 | Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. ( Bezuhly, M; Boudreau, C; Gratzer, P; LeVatte, T; Marshall, J; Midgen, C; Murphy, A, 2019) |
| "Losartan treatment had no impact on growth or kidney development." | 1.43 | Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. ( Béland-Bonenfant, S; Bertagnolli, M; Cloutier, A; Dios, A; Gascon, G; Lukaszewski, MA; Nuyt, AM; Paradis, P; Schiffrin, EL; Sutherland, M, 2016) |
| " The described method was successfully applied to preclinical pharmacokinetic studies of analytes after an oral administration of mixture of MET (1 mg/kg) and LOS (10 mg/kg) in rats." | 1.42 | Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS. ( Dubey, R; Ghosh, M; Muthukrishnan, V; Sinha, BN, 2015) |
| "Losartan is an effective anti-hypotension drug frequently used in clinic." | 1.39 | Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry. ( Chai, Y; Ma, W; Sun, S; Wang, B; Yuan, Y; Zhang, G; Zhang, H; Zhao, L, 2013) |
| "Treatment with losartan (15 mg/kg/day; n = 9) similarly mitigated signs of cardiac oxidative stress, but impairments in diastolic function persisted when compared with untreated rats (n = 7)." | 1.38 | Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats. ( Carter, CS; Groban, L; Kassik, KA; Lin, MS; Lindsey, S; Machado, FS; Wang, H, 2012) |
| "Cotreatment with GW9662, a peroxisome proliferator-activated receptor-γ antagonist, interfered with these protective effects of telmisartan against cognitive function." | 1.38 | Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. ( Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Shudou, M; Tsukuda, K, 2012) |
| " This method was successfully applied for pharmacokinetic study after oral administration of irbesartan (300 mg) to 23 Korean healthy male volunteers." | 1.35 | HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ( Bae, SK; Cho, DY; Kim, EY; Kim, MJ; Liu, KH; Shim, EJ; Shin, JG; Shon, JH, 2009) |
| "Hydroflumethiazide (HFTZ) was used as an internal standard (IS)." | 1.35 | Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ( Kundlik, ML; Patel, CN; Patel, DM; Patel, NK; Shah, HJ; Subbaiah, G; Suhagia, BN, 2009) |
| " A first-derivative UV spectroscopic method and HPLC were developed for the determination of losartan in the tablet dosage form." | 1.32 | A comparative study of first-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of losartan potassium in tablets. ( Ansari, M; Baradaran, M; Kazemipour, M; Khosravi, F, 2004) |
| "Two new rapid reproducible and economical spectrophotometric methods are described for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage forms." | 1.31 | A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form. ( Giridhar, R; Prabhakar, AH, 2002) |
| "Losartan potassium is an angiotensin II receptor blocker." | 1.30 | Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography. ( Brooks, MA; Gilbert, RE; Ip, DP; McCarthy, KE; Tsai, EW; Wang, Q, 1998) |
| "Losartan treatment was used to determine the role of angiotensin II (AngII) AT1 receptors in the inhibition of nNOS expression in 5/6 Nx." | 1.30 | Downregulation of neuronal nitric oxide synthase in the rat remnant kidney. ( Burns, KD; Fryer, JN; Levine, DZ; Roczniak, A, 1999) |
| "Losartan treatment of CRF rats before the removal of colonic tissues reversed the basal net secretion of urate to net absorption." | 1.29 | Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. ( Freel, RW; Hatch, M; Shahinfar, S; Vaziri, ND, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (28.57) | 18.2507 |
| 2000's | 25 (51.02) | 29.6817 |
| 2010's | 9 (18.37) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Bernhart, CA | 1 |
| Perreaut, PM | 1 |
| Ferrari, BP | 1 |
| Muneaux, YA | 1 |
| Assens, JL | 1 |
| Clément, J | 1 |
| Haudricourt, F | 1 |
| Muneaux, CF | 1 |
| Taillades, JE | 1 |
| Vignal, MA | 1 |
| Iwamura, A | 1 |
| Fukami, T | 1 |
| Hosomi, H | 1 |
| Nakajima, M | 1 |
| Yokoi, T | 1 |
| Eagles, SK | 1 |
| Wang, X | 1 |
| Gross, AS | 1 |
| McLachlan, AJ | 1 |
| Murphy, A | 1 |
| LeVatte, T | 1 |
| Boudreau, C | 1 |
| Midgen, C | 1 |
| Gratzer, P | 1 |
| Marshall, J | 1 |
| Bezuhly, M | 1 |
| Yuan, Y | 1 |
| Zhang, H | 1 |
| Ma, W | 1 |
| Sun, S | 1 |
| Wang, B | 1 |
| Zhao, L | 1 |
| Zhang, G | 1 |
| Chai, Y | 1 |
| Dubey, R | 1 |
| Ghosh, M | 1 |
| Sinha, BN | 1 |
| Muthukrishnan, V | 1 |
| Bertagnolli, M | 1 |
| Dios, A | 1 |
| Béland-Bonenfant, S | 1 |
| Gascon, G | 1 |
| Sutherland, M | 1 |
| Lukaszewski, MA | 1 |
| Cloutier, A | 1 |
| Paradis, P | 1 |
| Schiffrin, EL | 1 |
| Nuyt, AM | 1 |
| Teschemacher, AG | 1 |
| Wang, S | 1 |
| Raizada, MK | 1 |
| Paton, JF | 1 |
| Kasparov, S | 1 |
| Biederman, RW | 1 |
| Doyle, M | 1 |
| Young, AA | 1 |
| Devereux, RB | 1 |
| Kortright, E | 1 |
| Perry, G | 1 |
| Bella, JN | 1 |
| Oparil, S | 1 |
| Calhoun, D | 1 |
| Pohost, GM | 1 |
| Dell'Italia, LJ | 1 |
| Aksnes, TA | 1 |
| Flaa, A | 1 |
| Sevre, K | 1 |
| Mundal, HH | 1 |
| Rostrup, M | 1 |
| Kjeldsen, SE | 2 |
| Bae, SK | 1 |
| Kim, MJ | 1 |
| Shim, EJ | 1 |
| Cho, DY | 1 |
| Shon, JH | 1 |
| Liu, KH | 1 |
| Kim, EY | 1 |
| Shin, JG | 1 |
| del Rosario Brunetto, M | 1 |
| Contreras, Y | 1 |
| Clavijo, S | 1 |
| Torres, D | 1 |
| Delgado, Y | 1 |
| Ovalles, F | 1 |
| Ayala, C | 1 |
| Gallignani, M | 1 |
| Estela, JM | 1 |
| Martin, VC | 1 |
| Shah, HJ | 1 |
| Kundlik, ML | 1 |
| Patel, NK | 1 |
| Subbaiah, G | 1 |
| Patel, DM | 1 |
| Suhagia, BN | 1 |
| Patel, CN | 1 |
| Salvadori, MC | 1 |
| Moreira, RF | 1 |
| Borges, BC | 1 |
| Andraus, MH | 1 |
| Azevedo, CP | 1 |
| Moreno, RA | 1 |
| Borges, NC | 1 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Groban, L | 1 |
| Lindsey, S | 1 |
| Wang, H | 1 |
| Lin, MS | 1 |
| Kassik, KA | 1 |
| Machado, FS | 1 |
| Carter, CS | 1 |
| Min, LJ | 1 |
| Mogi, M | 1 |
| Shudou, M | 1 |
| Jing, F | 1 |
| Tsukuda, K | 1 |
| Ohshima, K | 1 |
| Iwanami, J | 1 |
| Horiuchi, M | 1 |
| Rao, RN | 1 |
| Raju, SS | 1 |
| Vali, RM | 1 |
| Sankar, GG | 1 |
| Dawson, A | 1 |
| Rana, BS | 1 |
| Pringle, SD | 1 |
| Donnelly, LA | 1 |
| Morris, AD | 1 |
| Struthers, AD | 1 |
| Allabi, AC | 1 |
| Gala, JL | 1 |
| Horsmans, Y | 1 |
| Babaoglu, MO | 1 |
| Bozkurt, A | 1 |
| Heusterspreute, M | 1 |
| Yasar, U | 1 |
| Ansari, M | 1 |
| Kazemipour, M | 1 |
| Khosravi, F | 1 |
| Baradaran, M | 1 |
| Günay, EC | 1 |
| Oztürk, MH | 1 |
| Ergün, EL | 1 |
| Altun, B | 1 |
| Salanci, BV | 1 |
| Uğur, O | 1 |
| Cil, B | 1 |
| Hekimoğlu, B | 1 |
| Caner, B | 1 |
| Wolf, SC | 1 |
| Sauter, G | 1 |
| Risler, T | 1 |
| Brehm, BR | 1 |
| Vogt, L | 1 |
| Laverman, GD | 1 |
| van Tol, A | 1 |
| Groen, AK | 1 |
| Navis, G | 1 |
| Dullaart, RP | 1 |
| Zhang, M | 1 |
| Wei, F | 1 |
| Zhang, YF | 1 |
| Nie, J | 1 |
| Feng, YQ | 1 |
| Kolocouri, F | 1 |
| Dotsikas, Y | 1 |
| Apostolou, C | 1 |
| Kousoulos, C | 1 |
| Loukas, YL | 1 |
| Perez-Ruiz, F | 1 |
| Wösten-van Asperen, RM | 1 |
| Lutter, R | 1 |
| Haitsma, JJ | 1 |
| Merkus, MP | 1 |
| van Woensel, JB | 1 |
| van der Loos, CM | 1 |
| Florquin, S | 1 |
| Lachmann, B | 1 |
| Bos, AP | 1 |
| Lin, C | 1 |
| Baker, KM | 1 |
| Thekkumkara, TJ | 1 |
| Dostal, DE | 1 |
| Hatch, M | 1 |
| Freel, RW | 1 |
| Shahinfar, S | 1 |
| Vaziri, ND | 1 |
| Williams, RC | 1 |
| Alasandro, MS | 1 |
| Fasone, VL | 1 |
| Boucher, RJ | 1 |
| Edwards, JF | 1 |
| Liénard, F | 1 |
| Thornton, SN | 1 |
| Martial, FP | 1 |
| Mousseau, MC | 1 |
| Galaverna, O | 1 |
| Meile, MJ | 1 |
| Nicolaïdis, S | 1 |
| Ritter, MA | 1 |
| Furtek, CI | 1 |
| Lo, MW | 1 |
| Farthing, D | 1 |
| Sica, D | 1 |
| Fakhry, I | 1 |
| Pedro, A | 1 |
| Gehr, TW | 1 |
| Soldner, A | 2 |
| Spahn-Langguth, H | 2 |
| Mutschler, E | 2 |
| Palm, D | 1 |
| McCarthy, KE | 1 |
| Wang, Q | 1 |
| Tsai, EW | 1 |
| Gilbert, RE | 1 |
| Ip, DP | 1 |
| Brooks, MA | 1 |
| Merlos, M | 1 |
| Rabasseda, X | 1 |
| Silvestre, JS | 1 |
| Lee, SH | 1 |
| Jung, YS | 1 |
| Lee, BH | 1 |
| Yun, SI | 1 |
| Yoo, SE | 1 |
| Shin, HS | 1 |
| Roczniak, A | 1 |
| Fryer, JN | 1 |
| Levine, DZ | 1 |
| Burns, KD | 1 |
| Iwasa, T | 1 |
| Takano, T | 1 |
| Hara, K | 1 |
| Kamei, T | 1 |
| Carlucci, G | 1 |
| Palumbo, G | 1 |
| Mazzeo, P | 1 |
| Quaglia, MG | 1 |
| Erk, N | 1 |
| Silva-Antonialli, MM | 1 |
| Fortes, ZB | 1 |
| Carvalho, MH | 1 |
| Scivoletto, R | 1 |
| Nigro, D | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Preti, P | 1 |
| Fogari, E | 1 |
| Malamani, G | 1 |
| Mugellini, A | 1 |
| Shimada, N | 1 |
| Hayashi, K | 1 |
| Saka, S | 1 |
| Nakamura, T | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Prabhakar, AH | 1 |
| Giridhar, R | 1 |
| De Rosa, ML | 1 |
| Cardace, P | 1 |
| Rossi, M | 1 |
| Baiano, A | 1 |
| de Cristofaro, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars[NCT05259137] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for losartan and Sensitivity and Specificity
| Article | Year |
|---|---|
Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Hu | 1998 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
6 trials available for losartan and Sensitivity and Specificity
| Article | Year |
|---|---|
Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Doubl | 2008 |
Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics.
Topics: Administration, Oral; Adult; Chlorthalidone; Chromatography, High Pressure Liquid; Cross-Over Studie | 2009 |
Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Dose-Response Relation | 2005 |
A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Proteins; Chromatogr | 1998 |
Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Bl | 2001 |
Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.
Topics: Analysis of Variance; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2002 |
41 other studies available for losartan and Sensitivity and Specificity
| Article | Year |
|---|---|
A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Female; Imidazoles; I | 1993 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxyge | 2011 |
An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma.
Topics: Biosensing Techniques; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Syste | 2020 |
Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Movement; Cells, Cultured; Cicatrix, Hypertro | 2019 |
Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry.
Topics: Animals; Chromatography, Liquid; Drug Stability; Drugs, Chinese Herbal; Herb-Drug Interactions; Imid | 2013 |
Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS.
Topics: Animals; Chromatography, High Pressure Liquid; Linear Models; Losartan; Male; Metolazone; Rats; Rats | 2015 |
Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cardiomegaly; Disease Models, An | 2016 |
Area-specific differences in transmitter release in central catecholaminergic neurons of spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Brain Stem; Catecholamines; Disease Models, Animal; Dopamine beta-Hydroxyla | 2008 |
Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Determination; Dose-Response Relati | 2008 |
HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies.
Topics: Acetonitriles; Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chromatography, H | 2009 |
Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a column-switching liquid chromatographic system with fluorescence detection.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Chromatography, High Pressure Liquid; Humans; Lo | 2009 |
Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS.
Topics: Acids; Antihypertensive Agents; Chromatography, Liquid; Humans; Hydroflumethiazide; Imidazoles; Losa | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.
Topics: Aging; Analysis of Variance; Animals; Arterial Pressure; Diastole; Disease Models, Animal; Dose-Resp | 2012 |
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Be | 2012 |
Liquid chromatography-mass spectrometric determination of losartan and its active metabolite on dried blood spots.
Topics: Animals; Chromatography, Liquid; Dried Blood Spot Testing; Drug Stability; Linear Models; Losartan; | 2012 |
How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Echocardiography; Electroc | 2004 |
Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.
Topics: Administration, Oral; Adult; Alleles; Aryl Hydrocarbon Hydroxylases; Biological Availability; Black | 2004 |
A comparative study of first-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of losartan potassium in tablets.
Topics: Chromatography, High Pressure Liquid; Costs and Cost Analysis; Losartan; Reproducibility of Results; | 2004 |
Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2005 |
Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.
Topics: Adult; Analysis of Variance; Apolipoproteins; Biological Transport; Case-Control Studies; Cholestero | 2006 |
Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Ele | 2006 |
Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry.
Topics: Antihypertensive Agents; Chemical Fractionation; Drug Combinations; Drug Monitoring; Humans; Hydroch | 2007 |
New treatments for gout.
Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Se | 2007 |
ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin.
Topics: Angiotensin II; Animals; Apoptosis; Bradykinin; Bronchoalveolar Lavage Fluid; Captopril; Disease Mod | 2008 |
Sensitive bioassay for the detection and quantification of angiotensin II in tissue culture medium.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biological Assay; Biphenyl Compounds; Cal | 1995 |
Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Trans | 1996 |
Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets.
Topics: Antihypertensive Agents; Biphenyl Compounds; Chromatography, High Pressure Liquid; Electrophoresis, | 1996 |
Effects of DOCA pretreatment on neuronal sensitivity and cell responsiveness to angiotensin II, in the bed nucleus of the stria terminalis in the rat.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Desoxyco | 1996 |
An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Chromatography, High | 1997 |
Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Dialysis Solutions; Humans; Imidazole | 1997 |
HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chromatography, H | 1998 |
Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography.
Topics: Antihypertensive Agents; Chromatography, Thin Layer; Losartan; Molecular Structure; Reproducibility | 1998 |
Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1999 |
Downregulation of neuronal nitric oxide synthase in the rat remnant kidney.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Blotting, Western; Cell Nucleus; Cu | 1999 |
Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.
Topics: Antihypertensive Agents; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Losartan; Mass | 1999 |
Simultaneous determination of losartan and hydrochlorothiazide in tablets by high-performance liquid chromatography.
Topics: Antihypertensive Agents; Calibration; Chromatography, High Pressure Liquid; Diuretics; Hydrochloroth | 2000 |
Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique.
Topics: Chromatography, High Pressure Liquid; Hydrochlorothiazide; Losartan; Reproducibility of Results; Sen | 2001 |
Sexual dimorphism in the response of thoracic aorta from SHRs to losartan.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Disease Models, An | 2000 |
Does angiotensin II receptor antagonist Losartan suppress drinking behavior in hemodialysis patients?
Topics: Aged; Drinking Behavior; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kidney Fai | 2001 |
A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form.
Topics: Antihypertensive Agents; Colorimetry; Hydrogen-Ion Concentration; Losartan; Sensitivity and Specific | 2002 |